Our data indicated that a higher ratio of CD8+/Treg has a beneficial effect on clinical outcome in LGG and GBM (Figure 11G,H), but we did not observe a significant difference in the ratio of anti-/pro-tumor modulators, nor the ratio of M1/M2. The gene discussed is CD8A; the disease is neoplasm.